AstraZeneca PLC (LON:AZN)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 160.03B |
| Revenue (ttm) | 43.19B |
| Net Income (ttm) | 5.62B |
| Shares Out | 1.55B |
| EPS (ttm) | 3.59 |
| PE Ratio | 28.71 |
| Forward PE | 15.12 |
| Dividend | 2.46 (2.38%) |
| Ex-Dividend Date | Feb 20, 2025 |
| Volume | 3,674,527 |
| Average Volume | 2,474,302 |
| Open | 10,260 |
| Previous Close | 10,320 |
| Day's Range | 10,198 - 10,336 |
| 52-Week Range | 9,574 - 13,388 |
| Beta | 0.25 |
| RSI | 39.01 |
| Earnings Date | Apr 29, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...
Trump says US pharma tariffs coming in not-too-distant future
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
This Pharma Giant Will Invest $23 Billion in the U.S. It's a Sign Trump's Tariffs Are Working.
The Company spend billions to produce 100% of its key medicines for Americans in the U.S.
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties...
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturin...
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squ...
Global pharma shares plunge as Trump doubles down on tariff threat
Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain, and...
Trump teases targeted tariffs on overseas drug manufacturers
With the next set of White House–imposed tariffs just hours away from taking effect — including the attention-hogging 104% rate to be levied on products from China as they're imported into the U.S. — ...
Daiichi Sankyo and AstraZeneca get EU approval for Datroway
Teva, Samsung Bioepis launch biosimilar against AstraZeneca’s Soliris
China, America and pay inject drama into AstraZeneca’s AGM
The boss’s bonus is an annual debating point at Britain’s biggest company. But that’s not the only issue this year AstraZeneca is used to facing protests over pay at its annual general meetings, given...
AstraZeneca's Innovation Ecosystem: From Blockbusters To The Next Generation Of Therapy
European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings
The European Commission on Friday approved AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSKNY) Enhertu (trastuzumab deruxtecan) as a monotherapy for a type of breast cancer. The approval...
AstraZeneca's metastatic breast cancer treatment gets EU nod
Pharma tariff relief likely short-lived with sector-specific duties on the horizon
Pharmaceutical companies breathed a sigh of relief Wednesday after U.S. President Donald Trump revealed that they would not be subject to reciprocal tariffs — but that reprieve could prove fleeting. T...
Pharma stocks survive market rout on tariff exemption, but uncertainty continues
Drugmaker stocks gained a temporary reprieve on Thursday as U.S. President Donald Trump spared pharmaceutical products from reciprocal tariffs, but executives and analysts warned it was premature to c...
Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
Peering Into AstraZeneca's Recent Short Interest
AstraZeneca's (NYSE: AZN) short percent of float has fallen 10.91% since its last report. The company recently reported that it has 15.24 million shares sold short , which is 0.49% of all regular sha...
OncoHelix and AstraZeneca Partner to Provide Access to Liquid Biopsy Testing for Men with Prostate Cancer
CALGARY, AB , April 1, 2025 /CNW/ - OncoHelix, a leader in precision diagnostics, is proud to announce its partnership with AstraZeneca Canada to deliver cutting-edge liquid biopsy testing for men wit...
FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by...